Showing results (1651-1660 of 1,705) with videos related to

Sort By:
Pageof 171
Nature Communications|December 12, 2024
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastomaJourdin R C Rouaen, Antonietta Salerno, Tyler Shai-Hee, et al.
Nature Neuroscience|March 22, 2016
C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteinsYong-Jie Zhang, Tania F Gendron, Jonathan C Grima, et al.
Marine Genomics|October 4, 2017
Cross-disciplinarity in the advance of Antarctic ecosystem researchJ Gutt, E Isla, A N Bertler, et al.
Neurology|June 27, 2025
An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related DisordersLeland Barnard, Hugo Botha, Nick Corriveau-Lecavalier, et al.
The Lancet. Neurology|January 24, 2024
Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysisMarianne Chapleau, Renaud La Joie, Keir Yong, et al.
Annals of Neurology|November 7, 2025
Association between Human Leukocyte Antigen Alleles and Neuropathological Outcomes in Lewy Body DiseaseMarios Gavrielatos, Michael G Heckman, Alexandra I Soto-Beasley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 23, 2018
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathologyRenaud La Joie, Nagehan Ayakta, William W Seeley, et al.
Neurobiology of Aging|May 29, 2014
Ataxin-2 as potential disease modifier in C9ORF72 expansion carriersMarka van Blitterswijk, Bianca Mullen, Michael G Heckman, et al.
Nature Communications|June 20, 2024
Gliovascular transcriptional perturbations in Alzheimer's disease reveal molecular mechanisms of blood brain barrier dysfunctionÖzkan İş, Xue Wang, Joseph S Reddy, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 23, 2026
Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to actionNick Corriveau-Lecavalier, Neus Falgàs, Deepti Putcha, et al.
Pageof 171